Abstract
Introduction and objective: In Colombia, Dipeptidyl-Peptidase IV (DPP4) inhibitors are recommended as second-best choice for type 2 diabetes mellitus treatment. However, no evaluation of the accomplishment or impact of this recommendation was performed. The objective was to determine the prescription of the DPP4 inhibitor according to the Colombian Clinicial Practice Guide regarding type 2 diabetes mellitus treatment, and its effects on glycosylated hemoglobin (HbA1c). Materials and methods: A descriptive study that included patients with type 2 diabetes mellitus who attended a first level between 2016 and 2018, had a prescription for DPP4 inhibitor and at least two control appointments. Variables included were sociodemographic, clinics, treatment and comorbidities. The unadjusted prescription was defined as the lack of accomplishment of Colombian guidelines. Descriptive statistics and X2 test were used for the comparison of categorical variables. A binary logistic regression model was applied. Results: 112 out of 207 patients accomplished inclusion criteria, of which 77 were women (68.8%). Also, 68.8% of the patients had an unadjusted prescription of the iDPP4. There was a 0.21% total reduction in HbA1c levels, with a mean of 198.2 ± 124 days between the first and second control measurement (reduction of 0.55% when the prescription was adjusted to the guidelines and 0.05% if it was unadjusted). Conclusion: There is a limited impact of DPP4 inhibitors regarding the reduction of HbA1c and metabolic control, and there is a slight follow-up to the Colombian guidelines in patients who attend a first level.
Publisher
Universidad Industrial de Santander
Reference30 articles.
1. 1. Federación Internacional de Diabetes. Atlas de la Diabetes de la FID. 2017. http://www.fundaciondiabetes.org/upload/publicaciones_ficheros/95/IDF_Atlas_2015_SP_WEB_oct2016.pdf
2. 2. Organización Mundial de la salud. Informe mundial sobre la Diabetes. Resumen de orientación. 2017. http://apps.who.int/iris/bitstream/10665/204877/1/WHO_NMH_NVI_16.3_spa.pdf?ua=1
3. 3. Aschner P. Epidemiología de la diabetes en Colombia. Av Diabetol. 2010; 26: 95-100. https://doi.org/10.1016/S1134-3230(10)62005-4
4. 4. Instituto Nacional de Salud. Carga de enfermedad por Enfermedades Crónicas No Transmisibles y Discapacidad en Colombia. Informe técnico. 2017. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/IA/INS/informe-ons-5.pdf
5. Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults;Aschner;Colomb Med,2016